HONG KONG – The market for expensive blood products in China is attracting biotech companies looking to boost their bottom lines, but a surge in imports, driven by high supply levels abroad, is pressuring the bottom lines of domestic suppliers. Read More

SHANGHAI – Advaxis Inc. signed an exclusive licensing agreement with newly minted Global Biopharma Inc. (GBP), of Taiwan, to develop and commercialize ADXH-HPV, an immunotherapy treatment for human papillomavirus (HPV) associated diseases. Read More

SHANGHAI – Amgen Inc. entered China in 2012, more than a decade after most other global players in the industry. While some may think the big biotech is a late comer, company execs say the time is just right to develop innovative drugs in a country where most drug makers focus on generics. Read More

HONG KONG – Multinational biopharmaceutical companies are looking beyond China and paying more attention to emerging markets in Asia, even as local companies are looking outward from their home markets and using biosimilars as their ladders to climb up to the global market. Read More

Qrxpharma Ltd., of Sydney, said the FDA established May 25, 2014, as the new Prescription Drug User Fee Act date for action on the company’s refiled new drug application for immediate-release Moxduo, a version of hydrocodone and morphine. The FDA will schedule an advisory committee meeting prior to that date, and assuming approval, the company said it plans to launch the product in the U.S. in the second half of 2014. Read More